In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series E brings $79mm to Nuvaira

Executive Summary

Nuvaira Inc. (formerly Holaira; medical devices to treat obstructive lung diseases) raised $79mm in its Series E financing led by US Venture Partners, which was joined by other new backers Endeavour Vision, Qiming Venture Partners, Lightstone Ventures, and Richard King Mellon Foundation and returning shareholders Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, Versant Ventures, Vertex Venture Holdings, and Windham Venture Partners. The company will use the funds for the pivotal AIRFLOW-3 clinical trial of its lung denervation system required to gain FDA approval, and to create a clinical development strategy in key markets in Europe.
Deal Industry
  • Medical Devices
    • Radiofrequency Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies